Please login to the form below

Not currently logged in
Email:
Password:

Parexel strengthens clinical leadership

Accenture MD Roland Andersson and Grunenthal’s Thomas Senderovitz join CRO

Parexel roland_andersson Parexel has named two new senior VPs within its clinical research services unit.

Dr Roland Andersson (pictured) joins the contract research organisation (CRO) from consultancy Accenture where he was managing director, while Dr Thomas Senderovitz joins from German pharma company Grunenthal, where he was executive VP of global compound development.

At Parexel the two new recruits will be involved in developing and implementing its global corporate objectives backed by a broad experience of the life sciences industry.

Dr Andersson's specific responsibilities include managing client relationships for phase II and phase III programmes on a global basis.

This follows on from his role at Accenture where he oversaw technology, consulting and business services for leading pharma and biotech companies. At Accenture, he was vital in the creation of TransCelerate BioPharma, an industry group that aligns companies to address common drug development problems

Dr Senderovitz will have responsibility for the management of Parexel's early phase and clinical logistics business units, as well as the global medical services function.

His past experience at Grunenthal includes providing strategic development and project oversight for all clinical development functions, including early clinical development, late stage clinical development, global clinical operations and global biometrics.

Prior to joining Grunenthal Dr Senderovitz served as VP of global exploratory development at UCB and VP of clinical R&D at Ferring Pharmaceuticals.

9th April 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....